<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581320</url>
  </required_header>
  <id_info>
    <org_study_id>DP-CTR206-03</org_study_id>
    <nct_id>NCT01581320</nct_id>
  </id_info>
  <brief_title>Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis</brief_title>
  <acronym>DIOS</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R206 and Bonviva for the Improvement of Vitamin D in Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alvogen Korea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alvogen Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, active-controlled, phase III clinical trial to
      evaluate the efficacy and safety of Dp-R206 and Bonviva for 16 weeks once a month on the
      improvement of vitamin D in postmenopausal women with osteoporosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A ratio of subject whose 25 OHD concentration is less than 15ng/mL</measure>
    <time_frame>16weeks</time_frame>
    <description>A ratio of subject whose 25 OHD concentration is less than 15ng/mL after 16weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A ratio of subject whose 25 OHD concentration is less than 9ng/mL</measure>
    <time_frame>16 weeks</time_frame>
    <description>A ratio of subject whose 25 OHD concentration is less than 9ng/mL after 16weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety evaluation (AE, Lab test, Vital sign etc)</measure>
    <time_frame>16weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">201</enrollment>
  <condition>Postmenopausal Women With Osteoporosis</condition>
  <arm_group>
    <arm_group_label>DP-R206</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bonviva</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test group</intervention_name>
    <description>Once a month, administration of DP-R206 &amp; placebo for 16 weeks</description>
    <arm_group_label>DP-R206</arm_group_label>
    <other_name>DP-R206 (Test drug)</other_name>
    <other_name>&lt;Ibandronate 150mg + cholecalciferol(Vitamin D3) 24,000IU&gt;</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reference group</intervention_name>
    <description>Once a month, administration of Bonviva &amp; placebo for 16 weeks</description>
    <arm_group_label>Bonviva</arm_group_label>
    <other_name>BonvivaÂ®</other_name>
    <other_name>(Ibandronate 150mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female more than 40 years old in postmenopausal

        Exclusion Criteria:

          -  Subject who has a history of malignant cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Moo-il Kang, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2012</study_first_submitted>
  <study_first_submitted_qc>April 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>October 31, 2016</last_update_submitted>
  <last_update_submitted_qc>October 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Ibandronic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

